


Unmasking the Hidden Threat:

Mycoplasma genitalium

In the ever-evolving world of diagnostics, a proactive approach is crucial to providing exceptional patient care. HNL Lab Medicine proudly presents its convenient *Mycoplasma genitalium* testing, a comprehensive solution for detecting *M. genitalium* infections. Through an extensive prevalence study, in partnership with Hologic, we have unveiled insights that highlight the urgent need for *M. genitalium* testing in local patient populations.




About *M. genitalium*

M. genitalium is a sexually transmitted bacterium belonging to the class Mollicutes. This infection is strongly associated with urethritis in men and cervicitis in women. Consequences of *M. genitalium* infections can include pelvic inflammatory disease (PID), preterm delivery, spontaneous abortion, and infertility.

M. genitalium infections largely go unrecognized, as infected individuals are either asymptomatic or have symptoms similar to those associated with other bacterial infections of the urogenital tract. *M. genitalium* testing is recommended by the Centers for Disease Control and Prevention for all recurrent episodes of cervicitis and nongonococcal urethritis. Testing should be considered for cases of PID.

Current treatment recommendations are focused on chlamydial, gonorrheal or trichomonal infections. However, antimicrobial therapy for these infections is organism-specific, and therapeutic regimens effective against these organisms have reduced efficacy for curing *M. genitalium* infections. Therefore, effective and comprehensive treatment relies on the detection of the appropriate organism, making *M. genitalium* testing necessary in certain circumstances.




Unveiling the Prevalance

Our study involved analyzing a total of 261 patient samples, encompassing a diverse range of cases. These samples were randomly selected from specimens collected for symptomatic and asymptomatic *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, and *Trichomonas vaginalis* testing.

The total positivity rate stood at 8%, which included 61 samples where *M. genitalium* testing was specifically ordered. Random testing of 200 additional samples, where *M. genitalium* was not initially flagged by clinicians, revealed a positivity rate of 6%.

This reveals the elusive nature of *M. genitalium*, making its inclusion an imperative element of symptomatic testing protocols.



6%
positive rate for
sample where
M.gen was not
ordered



Data-Driven Insights

Hard data speaks volumes. Our prevalence study findings emphasize the significance of *M. genitalium* testing. Our goal is to facilitate informed decision-making and encourage the inclusion of *M. genitalium* testing in symptomatic STI testing protocols. By sharing these prevalence study results, we aim to highlight the urgent need for proactive testing.

Contact HNL Lab Medicine today to discover how we can enhance your diagnostic capabilities and help you stay one step ahead of health concerns like *M. genitalium*. Empower your practice, protect your patients, and become a proponent of proactive healthcare. Together, we can make a tangible difference in the lives of those we serve.

Mycoplasma genitalium infections are a hidden threat with severe consequences. Early detection through *M. genitalium* testing is crucial for effective treatment and prevention of complications.

Data-driven insights from the study emphasize the need for proactive testing; HNL Lab Medicine aims to facilitate informed decision-making and encourage the inclusion of *M. genitalium* testing in symptomatic STI protocols.

By partnering with HNL Lab Medicine, healthcare providers can enhance their diagnostic capabilities and protect their patients from the risks associated with *M. genitalium* infections.